Cerebrolysin: Complete Guide to the Neuropeptide Mixture

Cerebrolysin sits in an unusual category: a porcine-derived peptide mixture with over five decades of clinical use abroad, hundreds of published trials, and zero approval in the United States. The signal is real, the noise is loud, and the protocol layer is where most users get it wrong. This guide unpacks the mechanism, the trial data across stroke, dementia and traumatic brain injury, the dosing logic, and the safety boundaries researchers should respect.

Key takeaways#

• Cerebrolysin is not a single peptide. It is an enzymatic hydrolysate of pig brain tissue, roughly 15% low-molecular-weight peptide fragments and 85% free amino acids by the manufacturer's description.
• The mechanism is receptor-mediated, not generalised: peptide fragments engage Trk receptors and mimic endogenous neurotrophic factors such as BDNF, NGF and GDNF.
• The strongest trial signals come from moderate-to-severe traumatic brain injury (CAPTAIN series) and mild-to-moderate Alzheimer's disease at 30 mL/day, with smaller and inconsistent effects in acute ischemic stroke.
• The European product label gives adult daily doses of 10-30 mL for Alzheimer's dementia and 20-50 mL for stroke and traumatic brain injury, mostly by slow intravenous infusion, in cycles of roughly 10-30 days that can be repeated. Higher is not reliably better.
• Cerebrolysin is not FDA-approved. It is registered in roughly 50 countries by the manufacturer's count, under varying evidentiary thresholds, and contraindicated in epilepsy, severe renal failure, and porcine allergy.

Cerebrolysin is a peptide hydrolysate, not a designer molecule#

The compound's biology starts with its source. Cerebrolysin is a neuropeptide preparation derived from porcine brain tissue through a controlled enzymatic hydrolysis process. The resulting compound is a mixture of low-molecular-weight peptide fragments and free amino acids, the most therapeutically significant of which can cross the blood-brain barrier.

That composition matters for dosing logic. By the manufacturer's own description, roughly 15% of the Cerebrolysin concentrate (measured by nitrogen content) consists of low-molecular-weight peptide fragments, and roughly 85% is free amino acids. The peptide fraction contains fragments with molecular weights below 10,000 daltons, a threshold considered important for blood-brain barrier permeability. Russian molecular-biological profiling has identified active peptide fragments of nerve growth factor, enkephalins, orexin, galanin within the mixture, which helps explain its multiple downstream actions.

The clinical relevance is that Cerebrolysin behaves less like a small molecule with one binding pocket and more like a broad neurotrophic stimulus. That distinction frames every trial result that follows.

The mechanism is receptor-mediated, not vague neuroprotection#

Older marketing material described Cerebrolysin as a generic "brain support" agent. The current mechanistic picture is more specific. Research suggests the active fragments engage tyrosine kinase receptors in the same family that BDNF and NGF use. Mechanistic reviews propose that Cerebrolysin's peptides engage Trk-family receptors and activate PI3K/Akt and MAPK/ERK signaling cascades, which have been shown to drive neuronal survival, dendritic spine formation, and endogenous BDNF upregulation.

Preclinical data points to measurable structural effects. Cultured-neuron work has shown increased dendritic spine density after exposure, with that effect blocked by Trk inhibitors, indicating receptor-dependent action rather than nonspecific trophic noise.

Animal stroke models have also been informative. Research has shown that Cerebrolysin augments the proliferation, differentiation, and migration of adult subventricular zone neural progenitor cells, contributing to neurogenesis , which may explain part of the post-stroke functional signal seen in larger trials.

Trial data is strongest in TBI and Alzheimer's, weakest in acute stroke#

This is where most internet write-ups overreach. The evidence base is not uniform across indications, and honest reading requires separating the strong signals from the weak ones.

Traumatic brain injury#

The CAPTAIN trial series is the cleanest dataset Cerebrolysin has. A prospective meta-analysis summarised results from the CAPTAIN trial series, evaluating Cerebrolysin for moderate-severe traumatic brain injury as an add-on to usual care. The study included two phase IIIb/IV prospective, randomized, double-blind, placebo-controlled clinical trials. Eligible patients with a Glasgow Coma Score between 6 and 12 received 50 mL of Cerebrolysin or saline per day for ten days, followed by two additional treatment cycles with 10 mL per day for 10 days.

The primary results: a small-to-medium sized effect in favour of Cerebrolysin, statistically significant at Day 30 and at Day 90 (Day 30: MWcombined = 0.60, p = 0.0156; Day 90: MWcombined = 0.60, p = 0.0146) . The pooled analysis covered 185 patients, so the effect is modest and the sample small. Read the CAPTAIN prospective meta-analysis in Neurological Sciences.

Alzheimer's disease#

In mild-to-moderate Alzheimer's, the 30 mL/day dose has the most replication. Studies have shown that Cerebrolysin was significantly more effective than placebo at 4 weeks for cognitive function (SMD -0.40 points; 95% CI -0.66 to -0.13; p = 0.0031) and at both 4 weeks and 6 months for global clinical change (4 weeks OR 3.32; 6 months OR 4.98) . A 2015 meta-analysis published in Dementia and Geriatric Cognitive Disorders concluded the compound has a favourable benefit-risk ratio in this population.

Dose-response is non-linear. In a 24-week trial, patients received iv infusions of 10, 30 or 60 mL Cerebrolysin or placebo five days/week for the first four weeks and thereafter two iv infusions per week for eight weeks . At week 24 only the 10 mL dose significantly improved cognition (ADAS-cog); the 30 and 60 mL doses improved global outcome but not cognition, which the authors read as an inverted U-shaped dose-response (Alvarez et al., 2006). More is not better.

Acute ischemic stroke#

Here the data is genuinely mixed. In a 100-patient randomized, double-blind, placebo-controlled multicenter trial in Iran, Cerebrolysin started within 18 hours of stroke onset showed a medium-to-large advantage over placebo on the NIHSS at day 30 (the primary endpoint), with similar effect sizes on the mRS and the CGI (Gharagozli et al., 2017). It was a small trial with a 30-day primary endpoint.

But a separate meta-analysis reached the opposite reading. According to that pooled analysis, no statistically significant result was detected for cerebrolysin in the analysis of mRS, BI, and safety outcomes compared with placebo, indicating that cerebrolysin seemed to be safe but of little benefit to acute ischemic stroke patients . A more recent 2025 systematic review of 14 RCTs found enhanced early neurological recovery with comparable safety, but acknowledged that long-term functional outcomes remain unconfirmed.

The largest single trial, CASTA (1,070 patients in Asia, 30 mL/day for 10 days), missed its primary endpoint at day 90; the signal in severe strokes (NIHSS above 12) came from a post hoc analysis (Heiss et al., 2012). The independent Cochrane review, most recently updated in 2023, found moderate-certainty evidence of no effect on all-cause death (Ziganshina et al., 2023).

The honest summary: Cerebrolysin may support early neurological recovery after ischemic stroke, but the effect on 90-day functional independence is not settled.

Dosing protocols depend on the indication, not on bodyweight#

Cerebrolysin is administered parenterally, intravenously or intramuscularly. Oral peptides of this size do not survive the gut. Standard published protocols cluster around the following ranges:

• Alzheimer's disease: 30 mL/day IV, 5 days per week for 4 weeks, often followed by a taper of 2 infusions per week for 8 weeks.
• Acute ischemic stroke: 30-50 mL/day IV for 10-21 days, started within 72 hours of onset, the range used across the placebo-controlled trials (Bornstein et al., 2018).
• Moderate-to-severe TBI: 50 mL/day IV for 10 days, then two follow-on cycles of 10 mL/day for 10 days each.
• Cognitive support outside these indications: lower-volume cycles of 5-10 mL/day circulate in nootropic communities. They sit below the labeled doses and have no trial behind them.

A 30 mL dose is the most validated reference point. As one current trial protocol notes, a dosage of 30 mL once daily of Cerebrolysin is considered to be effective for the treatment of mild to moderately severe Alzheimer's Disease as shown in clinical studies and it has also shown efficacy in preliminary stroke trials .

Cerebrolysin is supplied as a ready-to-use solution in ampoules, so there is no reconstitution step, and the label sets the infusion rules (doses above 10 mL are diluted and infused over 15 to 60 minutes). Klarovel's protocol engine does not include Cerebrolysin, so it never appears in a Klarovel protocol. For how Klarovel builds a protocol from the health questionnaire, see how it works.

Safety profile is favourable in trials but not risk-free#

Across pooled stroke data, the safety picture is mostly reassuring, with one caveat. A meta-analysis pooled 2202 patients from twelve randomized clinical trials, registering non-statistically significant differences between Cerebrolysin and placebo throughout main and subgroup analyses. The lowest rate of serious adverse events, as compared to placebo, was observed for the highest dose of Cerebrolysin (50 mL), highlighting a moderate reduction (RR = 0.6).

The 2023 Cochrane review read the stroke trials less favorably: no difference in total serious adverse events, but more people with non-fatal serious adverse events on Cerebrolysin (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1,335 participants; moderate certainty) (Ziganshina et al., 2023).

Common, transient adverse effects associated with Cerebrolysin in clinical experience include headache, dizziness, anxiety or agitation, weight changes, and a sensation of feeling hot. Injection-site reactions and nausea are also reported. Serious events are rare but include hypersensitivity (the compound is porcine-derived), rare seizure activity in predisposed individuals, and hypotension with overly rapid IV infusion.

Two contraindications deserve emphasis. The product label lists epilepsy and severe renal impairment as contraindications, alongside hypersensitivity to any component, and warns that in epilepsy it may increase seizure frequency (Croatian SmPC, HALMED). In pregnancy and breastfeeding the label asks for a benefit-risk decision rather than a blanket exclusion.

Regulatory status: approved abroad, unapproved in the US#

This is where users get tripped up by overstated availability claims. Cerebrolysin holds a national marketing authorisation in Austria and, by the manufacturer's count, is registered in around 50 countries, including Russia and China, for indications including acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease. The European Medicines Agency has not issued an EU-wide centralised approval; approvals are held at the national level in individual European countries, for example Croatia, where it is a restricted prescription medicine for Alzheimer's dementia, stroke and brain injury (HALMED).

The US picture is clearer: as of October 31, 2026, Cerebrolysin is not approved by the FDA for any indication, and it does not appear among the substances nominated for FDA's 503A compounding bulks list (FDA 503A categories), so there is no approved or compounded US supply. It is also not one of the six peptides in HHS's draft compounding enforcement-discretion policy published on October 30, 2026 (Federal Register).

Cerebrolysin has no Norwegian marketing authorisation (it has no listing in Felleskatalogen), and status elsewhere in Europe varies country by country. Klarovel does not sell Cerebrolysin or any other peptide; it publishes the evidence and builds the protocol layer. See disclosures for the full positioning.

Where Cerebrolysin fits relative to other neurotrophic peptides#

Several smaller synthetic peptides are studied alongside Cerebrolysin in nootropic and neurorecovery contexts, particularly Semax, Selank and Dihexa. They are not interchangeable. Cerebrolysin is a multi-peptide hydrolysate delivered parenterally over multi-week cycles; Semax is a single heptapeptide typically given intranasally; Dihexa is an oral angiotensin IV analog. Their US status now differs too: under HHS's draft policy of October 30, 2026, HHS does not intend to take enforcement action against 503A compounding of Semax free base for intranasal use only, as a single ingredient on a patient-specific prescription. That is not FDA approval and does not add Semax to the 503A bulks list (Federal Register). Cerebrolysin and dihexa are not covered. The combined action across these compounds is complementary rather than redundant, but only Cerebrolysin has a randomized-trial base running to thousands of patients, mostly in stroke and dementia.

Researchers stacking peptides should plan cycles around the longest agent (Cerebrolysin) and treat shorter-acting compounds as adjuncts during that window, not the other way around.

Direct comparisons: Cerebrolysin vs semax.

The bottom line on Cerebrolysin#

Cerebrolysin is one of the few peptide compounds with a multi-decade clinical record, hundreds of trials, and a defensible mechanistic story. It is also one of the most overhyped. The honest reading is that 30 mL/day cycles have shown reproducible effects in moderate Alzheimer's disease and the CAPTAIN TBI series, with weaker and less consistent benefit in acute ischemic stroke. It is not FDA-approved, it is not a casual nootropic, and it requires parenteral administration with proper screening.

If you or someone you care for is living with the after-effects of a stroke, a brain injury or a dementia diagnosis, take this evidence to the treating neurologist and track any change together. Where Cerebrolysin is approved it is a prescription medicine given by infusion under supervision, not a self-directed protocol. For Klarovel's own protocols, built from a health questionnaire and safety-checked by the Klarovel engine, see how it works.